Vaccine News and Research

Latest Vaccine News and Research

Bivalent BA.4-5 or BA.1 mRNA-booster given as a fourth dose associated with increased protection against COVID-19 hospitalization and death

Bivalent BA.4-5 or BA.1 mRNA-booster given as a fourth dose associated with increased protection against COVID-19 hospitalization and death

23 Jan 2023
SARS-CoV-2 Omicron XBB.1.5, CA.3.1, and CH.1.1 exhibit remarkable antibody resistance

SARS-CoV-2 Omicron XBB.1.5, CA.3.1, and CH.1.1 exhibit remarkable antibody resistance

23 Jan 2023
Phase I trial results from AdaptVac's COVID capsid virus-like particle vaccine

Phase I trial results from AdaptVac's COVID capsid virus-like particle vaccine

22 Jan 2023
People with hybrid immunity are the most protected against severe COVID-19 and reinfection

People with hybrid immunity are the most protected against severe COVID-19 and reinfection

20 Jan 2023
Longitudinal assessment of immunoglobulin G antibody responses to messenger ribonucleic acid vaccination doses and breakthrough infections

Longitudinal assessment of immunoglobulin G antibody responses to messenger ribonucleic acid vaccination doses and breakthrough infections

20 Jan 2023
How effective are prior SARS-CoV-2 infections and hybrid immunity against Omicron breakthrough infections?

How effective are prior SARS-CoV-2 infections and hybrid immunity against Omicron breakthrough infections?

20 Jan 2023
InDevR raises $9 million in series B financing and partners with bioMérieux

InDevR raises $9 million in series B financing and partners with bioMérieux

20 Jan 2023
WHO reports a severe case of avian (bird) flu in Ecuador

WHO reports a severe case of avian (bird) flu in Ecuador

20 Jan 2023
New trial evaluates Omicron BA.1–adapted BNT162b2 vaccine in older adults

New trial evaluates Omicron BA.1–adapted BNT162b2 vaccine in older adults

20 Jan 2023
WHO to launch council to accelerate the development of TB vaccine

WHO to launch council to accelerate the development of TB vaccine

20 Jan 2023
Study finds fewer cases of MIS-C during omicron wave of the pandemic than delta

Study finds fewer cases of MIS-C during omicron wave of the pandemic than delta

19 Jan 2023
Researchers find that study results converge on a consistent relationship between antibody levels and protection from COVID-19

Researchers find that study results converge on a consistent relationship between antibody levels and protection from COVID-19

19 Jan 2023
Vaccinated women well protected against severe COVID-19 symptoms, complications during pregnancy

Vaccinated women well protected against severe COVID-19 symptoms, complications during pregnancy

19 Jan 2023
How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

How do mutations in emergent SARS-CoV-2 Omicron variants affect viral function, human immunity, and recognition by therapeutic antibodies?

19 Jan 2023
T-cell immunity and antibody responses against SARS-CoV-2 among individuals registered in the Bangkok home health care service

T-cell immunity and antibody responses against SARS-CoV-2 among individuals registered in the Bangkok home health care service

18 Jan 2023
Epitope mapping reveals the humoral responses against the main SARS-CoV-2 structural proteins in infected patients from Africa

Epitope mapping reveals the humoral responses against the main SARS-CoV-2 structural proteins in infected patients from Africa

18 Jan 2023
Investigational vaccine regimen safe but did not provide protection against HIV acquisition

Investigational vaccine regimen safe but did not provide protection against HIV acquisition

18 Jan 2023
Accurate information about what most other people are doing can boost vaccine uptake

Accurate information about what most other people are doing can boost vaccine uptake

18 Jan 2023
Study sheds new light on how the B cell academy mounts a diverse immune response

Study sheds new light on how the B cell academy mounts a diverse immune response

18 Jan 2023
The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US

The efficacy of low-dose fluvoxamine compared with placebo for treating mild to moderate COVID-19 in the US

18 Jan 2023

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback